These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27417407)

  • 1. An adaptive design for updating the threshold value of a continuous biomarker.
    Spencer AV; Harbron C; Mander A; Wason J; Peers I
    Stat Med; 2016 Nov; 35(27):4909-4923. PubMed ID: 27417407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
    Wang SJ
    J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.
    Wang T; Wang X; George SL; Zhou H
    J Biopharm Stat; 2020 Nov; 30(6):1060-1076. PubMed ID: 33175640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment design with patient population augmentation.
    Yang B; Zhou Y; Zhang L; Cui L
    Contemp Clin Trials; 2015 May; 42():60-7. PubMed ID: 25746817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive biomarker basket design in phase II oncology trials.
    Liu S; Takeda K; Rong A
    Pharm Stat; 2023 Jan; 22(1):128-142. PubMed ID: 36163614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design considerations for two-stage enrichment clinical trials.
    Frieri R; Rosenberger WF; Flournoy N; Lin Z
    Biometrics; 2023 Sep; 79(3):2565-2576. PubMed ID: 36435977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functions.
    Matano F; Sambucini V
    Pharm Stat; 2016 Nov; 15(6):517-530. PubMed ID: 27766770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-to-event analysis with treatment arm selection at interim.
    Di Scala L; Glimm E
    Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):. PubMed ID: 25485277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.